Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MLC and aqueous humor cytokines in macular edema due to retinal vein occlusion
ChiCTR2300069732Phase 4Not yet recruiting
- Sponsor
- Qingdao Eye Hospital of Shandong First Medical University
- Start
- Apr 2023
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of aflibercept and ozurdex in macular edema (2 arms), sponsored by Qingdao Eye Hospital of Shandong First Medical University. Primary endpoint: macrophage-like cells at vitreoretinal interface. Planned start Apr 2023; status: not yet recruiting.
02
Drugs
afliberceptozurdex
03
Conditions
macular edema
Beyond the preview
Go deeper on ChiCTR2300069732.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300069732.